• Publications
  • Influence
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
Excerpt Infection is currently the major fatal complication of acute leukemia (1). Previous studies have indicated a relationship between leukopenia and the presence of infection in patients with a...
  • 2,212
  • 41
  • PDF
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
Angiogenesis has been associated with the growth, dissemination, and metastasis of solid tumors. The aims of this study were to evaluate the vascularity and the levels of angiogenic factors inExpand
  • 664
  • 38
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
PURPOSE To evaluate the efficacy and toxicity of Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone), a dose-intensive regimen, in adult acute lymphocytic leukemiaExpand
  • 660
  • 34
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
PURPOSE The purpose of this study was to assess the incidence, presenting characteristics, and treatment outcomes of Richter's syndrome (RS) and factors predicting response and survival. PATIENTSExpand
  • 203
  • 20
  • PDF
Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia
Modern intensive chemotherapy regimens have improved the prognosis for patients with adult acute lymphocytic leukemia (ALL). With these regimens, the complete response rates are now reported to be >Expand
  • 458
  • 17
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Accurate identification of patients likely to achieve long-progression-free survival (PFS) after chemoimmunotherapy is essential given the availability of less toxic alternatives, such as ibrutinib.Expand
  • 320
  • 16
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
Patients ≥ 70 years of age with acute myeloid leukemia (AML) have a poor prognosis. Recent studies suggested that intensive AML-type therapy is tolerated and may benefit most. We analyzed 446Expand
  • 261
  • 14
The Effect of 6-Mercaptopurine on the Duration of Steroid-induced Remissions in Acute Leukemia: A Model for Evaluation of Other Potentially Useful Therapy
The effect of 6-MP therapy on the duration of remissions induced by adrenal corticosteroids has been studied as a model for testing of new agents. Ninetytwo patients under age 20 entered the studyExpand
  • 269
  • 14
Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia
It is unknown whether patients with nonleukemic myeloid sarcoma (MS) and those with acute myeloid leukemia (AML) have similar responses to anti‐AML treatment. In the current study, the authorsExpand
  • 143
  • 13